{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Raynaud+Phenomenon+Secondary+to+Systemic+Sclerosis",
    "query": {
      "condition": "Raynaud Phenomenon Secondary to Systemic Sclerosis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Raynaud+Phenomenon+Secondary+to+Systemic+Sclerosis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T18:08:26.876Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07112183",
      "title": "Open Label Treprostinil Raynaud's Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Raynaud's Disease",
        "Raynaud Phenomena",
        "Raynauds"
      ],
      "interventions": [
        {
          "name": "Oral treprostinil (UT-15C) sustained release tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-10-15",
      "completion_date": "2029-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07112183"
    },
    {
      "nct_id": "NCT01072669",
      "title": "Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ischemia"
      ],
      "interventions": [
        {
          "name": "ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soumya Chatterjee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-02",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-05-03",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072669"
    },
    {
      "nct_id": "NCT04915950",
      "title": "A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Temanogrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-11-03",
      "completion_date": "2022-09-02",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04915950"
    },
    {
      "nct_id": "NCT03867097",
      "title": "Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo IV infusion",
          "type": "DRUG"
        },
        {
          "name": "Iloprost Injection, for intravenous use",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Civi Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2019-03-07",
      "completion_date": "2019-08-06",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867097"
    },
    {
      "nct_id": "NCT00707187",
      "title": "Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Cialis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2001-07",
      "completion_date": "2002-07",
      "has_results": false,
      "last_update_posted_date": "2008-06-30",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00707187"
    },
    {
      "nct_id": "NCT00048776",
      "title": "Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Raynaud's Disease"
      ],
      "interventions": [
        {
          "name": "Pletal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka America Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "5 Years to 16 Years"
      },
      "enrollment_count": 75,
      "start_date": "2001-10",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2005-07-19",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 19,
      "location_summary": "Anchorage, Alaska • Fresno, California • Madera, California + 16 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048776"
    },
    {
      "nct_id": "NCT02228850",
      "title": "Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Phenomenon Secondary to Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Alprostadil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 35,
      "start_date": "2014-11",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-03-22",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 4,
      "location_summary": "Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228850"
    },
    {
      "nct_id": "NCT01090492",
      "title": "PF-00489791 For The Treatment Of Raynaud's",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Disease",
        "Peripheral Vascular Disease"
      ],
      "interventions": [
        {
          "name": "PF-00489791",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 243,
      "start_date": "2010-08-04",
      "completion_date": "2011-05-31",
      "has_results": true,
      "last_update_posted_date": "2018-05-16",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 23,
      "location_summary": "Redwood City, California • Farmington, Connecticut • Washington D.C., District of Columbia + 19 more",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rockford",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01090492"
    },
    {
      "nct_id": "NCT00480753",
      "title": "Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Raynaud's Disease"
      ],
      "interventions": [
        {
          "name": "Nitroglycerin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediQuest Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 15,
      "start_date": "2007-05",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2007-12-24",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 1,
      "location_summary": "Albany, New York",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00480753"
    },
    {
      "nct_id": "NCT00266669",
      "title": "Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Raynaud's Disease"
      ],
      "interventions": [
        {
          "name": "Topical organogel with nitroglycerin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediQuest Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 200,
      "start_date": "2005-12",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2007-08-08",
      "last_synced_at": "2026-06-10T18:08:26.876Z",
      "location_count": 17,
      "location_summary": "Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00266669"
    }
  ]
}